Subcallosal Cingulate Gyrus Deep Brain Stimulation for TRD
DBS targeting the subcallosal cingulate gyrus to treat depressive symptoms resulted in response and remission rates of 75% and 62.5%.
Related Articles
Nocturia Caused by Expired Escitalopram
In this report, a case of nocturia caused by expired escitalopram in a patient with depressive symptoms is discussed.
Safe Delivery of TMS to Patients With Implanted Devices
Tendler et al argue that, in considering transcranial magnetic stimulation (TMS) treatment, providers should refer to recent guidelines and literature reports instead of universally excluding…
Cardiovascular Risk by SMI Subtype
Cardiovascular disease is the leading cause of death for people with serious mental illness. A clinical decision support tool produced a significant relative reduction in…
Postpartum Psychosis or Something Else?
ABSTRACT Psychosis is a psychiatric emergency that affects up to 1 in 500 women postpartum and can result from various etiologies. We present a case…
SNRIs and Hypertensive Disorders of Pregnancy
Hypertensive disorders of pregnancy (HDP) are a major complication. In this study, the risk of HDP with SNRIs (9.5%) was significantly higher than with SSRIs…
Bullying Among Children With Mental, Emotional, Developmental, or Behavioral Problems
This study assessed the prevalence and odds of bullying victimization among US children with 1 or more mental, emotional, developmental, or behavioral problems.
Common Methods of Suicide and Self-Inflicted Poisoning/Injury by Individuals With Major Depressive Disorder and Bipolar Disorder: A Nationwide Inpatient Sample Analysis
ABSTRACT Objective: Individuals with major depressive disorder (MDD) and bipolar disorder (BD) are at increased risk of suicide. The objective of this study was to…
Functional Disability in US Military Veterans
Improved identification and integrated clinical management of sociodemographic, military, and health risk factors may help mitigate disability risk and promote the maintenance of functional capacity…
Brain-Targeting Drug Similar to Ozempic Shows Promise in Parkinson’s
The new dual agonist drug, DA5-CH, shows promise in Parkinson’s disease trials, outperforming diabetes drug Ozempic in a rat model.
Neurobiological Correlates of Psilocybin Response in MDD
Transient functional brain changes with psilocybin therapy resemble the “brain reset” phenomenon and may serve as the putative predictors of psilocybin antidepressant response.